Ads
related to: ezetimibe drugbank side effects medication
Search results
Results From The WOW.Com Content Network
Serious side effects may include anaphylaxis, liver problems, depression, and muscle breakdown. [4] [5] Use in pregnancy and breastfeeding is of unclear safety. [10] Ezetimibe works by decreasing cholesterol absorption in the intestines. [5] Ezetimibe was approved for medical use in the United States in 2002. [4] It is available as a generic ...
Ezetimibe/atorvastatin (trade names Liptruzet, Atozet) is a cholesterol lowering combination drug. In the United States, it was approved in May 2013, by the Food and Drug Administration for the treatment of elevated low-density lipoprotein (LDL) in patients with primary or mixed hyperlipidemia as adjunctive therapy to diet. [ 1 ]
With median follow-up of 6 years, simvastatin+ezetimibe was found to reduce the primary outcome of CV mortality, major CV event, or nonfatal stroke (34.7% vs. 32.7%; P=0.016; NNT 50 per 7 years or NNT 350 per 1 year ). There was no reduction in all-cause or CV mortality with simvastatin+ezetimibe, though there was a reduction in MI and stroke. [6]
Nausea is one of the most frequently reported side effects when starting a GLP-1 medication, due to slowed-down digestion. Nausea may be related to overeating while taking these medications as well.
Bempedoic acid/ezetimibe, sold under the brand name Nexlizet among others, is a fixed-dose combination medication used for the treatment of high cholesterol. [1] [3] It is a combination of bempedoic acid and ezetimibe. [1] [2] The most common side effects are hyperuricemia (high blood levels of uric acid) and constipation. [2]
Ezetimibe/rosuvastatin, sold under the brand name Ridutrin among others, is a combination medication used to treat high cholesterol. [6] [7] In some countries it is sold as a kit or a pack containing two distinct pills. [8] [9] The combination was approved for medical use in the United States in March 2021. [4]
Lomitapide, sold under the brand name Juxtapid in the US and Lojuxta in the EU, is a medication used as a lipid-lowering agent for the treatment of familial hypercholesterolemia, developed by Aegerion Pharmaceuticals. [3] It has been tested in clinical trials as single treatment and in combinations with atorvastatin, ezetimibe and fenofibrate ...
Hyzetimibe is a pharmaceutical drug that inhibits cholesterol absorption. [1] [2] It targets the NPC1-like intracellular cholesterol transporter 1.[2]It reduces plasma levels of low-density lipoprotein cholesterol (LDL-C) by blocking the Niemann-Pick C1-like 1 protein, a transporter mainly found in the intestine that allows dietary cholesterol to enter the body from the intestinal lumen.